When should annual influenza vaccination be administered, and which age groups and high‑risk populations should receive the inactivated quadrivalent vaccine versus the live‑attenuated intranasal vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Influenza Vaccination Season: Timing and Vaccine Selection

Direct Answer

All persons aged ≥6 months should receive annual influenza vaccination, ideally during September or October, with inactivated quadrivalent vaccine (IIV4) appropriate for all age groups and live-attenuated intranasal vaccine (LAIV4) reserved only for healthy persons aged 2-49 years without contraindications. 1, 2, 3

Optimal Timing of Vaccination

Standard Timing for Most Recipients

  • Begin vaccination in September or October for persons requiring only one dose per season, as this provides optimal protection before peak influenza activity. 2, 3
  • Continue vaccination throughout the entire influenza season as long as viruses are circulating and unexpired vaccine remains available—even after community influenza activity has been documented. 4, 2, 3

Special Timing Considerations

  • Children aged 6 months through 8 years requiring 2 doses should receive their first dose as soon as vaccine becomes available, including during July and August, to allow completion of the second dose (administered ≥4 weeks later) by the end of October. 1, 2, 3
  • Adults aged ≥65 years and pregnant persons in the first or second trimester should avoid vaccination during July and August unless there is concern that later vaccination might not be possible, due to concerns about waning immunity before peak season. 2
  • Vaccination campaigns in October should focus primarily on high-risk groups (persons aged >50 years, children aged 6-59 months, pregnant women, persons with chronic conditions, and healthcare workers), with broader population vaccination continuing in November and beyond. 4

Age Groups and High-Risk Populations

Universal Recommendation

  • All persons aged ≥6 months should receive annual influenza vaccination regardless of health status, with rare exceptions only for severe allergic reactions to vaccine components or history of Guillain-Barré syndrome within 6 weeks of prior influenza vaccination. 4, 1, 3

Priority High-Risk Populations

  • Children aged 6 through 59 months (all children under 5 years). 4, 1, 3
  • Persons aged ≥50 years. 4, 1, 3
  • Pregnant women (all trimesters). 4, 1, 3
  • Persons with chronic medical conditions (including asthma, chronic obstructive pulmonary disease, diabetes, heart disease, immunocompromising conditions). 4, 1, 3
  • Residents of nursing homes and long-term care facilities. 1, 3
  • American Indian or Alaska Native persons and persons with extreme obesity (BMI ≥40). 1, 3
  • Healthcare personnel and household contacts/caregivers of high-risk persons, including contacts of children aged <5 years. 4, 1, 3

Vaccine Selection: Inactivated vs. Live-Attenuated

Inactivated Quadrivalent Vaccine (IIV4)

IIV4 is appropriate for all persons aged ≥6 months and is the preferred or only option for most populations. 1, 2

Who Should Receive IIV4:

  • All children aged 6 months through 23 months (LAIV4 not approved for this age). 4, 1
  • Pregnant women (LAIV4 contraindicated). 4, 1, 3
  • Immunocompromised persons (LAIV4 contraindicated). 4, 1, 3
  • Persons with asthma, chronic obstructive pulmonary disease, or cystic fibrosis (LAIV4 not recommended). 4, 1
  • Children aged 2-4 years with recurrent wheezing (LAIV4 contraindicated due to increased risk of asthma/reactive airways disease demonstrated in children aged 12-59 months). 4, 1
  • Persons aged ≥50 years (LAIV4 not approved). 4, 1
  • Contacts of severely immunocompromised persons requiring protected environments (LAIV4 not recommended due to potential viral shedding). 1

Enhanced Vaccines for Older Adults:

  • Adults aged ≥65 years should preferentially receive one of three enhanced formulations: high-dose quadrivalent IIV (HD-IIV4), adjuvanted quadrivalent IIV (aIIV4), or recombinant quadrivalent vaccine (RIV4), as these provide superior immunogenicity in this age group. 2, 3

Live-Attenuated Intranasal Vaccine (LAIV4)

LAIV4 is approved only for healthy persons aged 2-49 years without contraindications. 4, 1

Eligibility Criteria for LAIV4:

  • Age 2-49 years (not approved outside this range). 4, 1
  • Healthy status without chronic medical conditions. 4, 1
  • No history of recurrent wheezing in children aged 2-4 years. 4, 1
  • Not pregnant. 4, 1, 3
  • Not immunocompromised. 4, 1, 3
  • Not a close contact of severely immunocompromised persons. 1

Common Side Effects:

  • In children and adolescents, runny nose/nasal congestion (28-78%), headache (16-44%), and sore throat (15-27%) occur more frequently than with placebo. 4
  • In adults aged 18-49 years, runny nose (44.5% vs. 27.1% placebo), sore throat (27.8% vs. 17.1%), and tiredness/weakness (25.7% vs. 21.6%) are more common. 4

Dosing Schedules by Age

Children Aged 6 Months Through 8 Years

Two doses (separated by at least 4 weeks) are required if the child has received fewer than 2 total doses of influenza vaccine (any formulation, any season) before July 1 of the current season. 1, 2, 3

One dose per season is sufficient if the child has previously received ≥2 total doses of influenza vaccine administered ≥4 weeks apart at any time before July 1 of the current season (doses need not be from consecutive seasons). 1, 2

Children Aged ≥9 Years and All Adults

One dose per season regardless of vaccination history. 1, 2, 3

Dose Volumes for Young Children (IIV4):

  • Afluria Quadrivalent: 0.25 mL for ages 6-35 months; 0.5 mL for ≥36 months. 4, 2
  • Fluzone Quadrivalent: Either 0.25 mL or 0.5 mL for ages 6-35 months; 0.5 mL for ≥36 months. 4, 2
  • Fluarix, Flucelvax, FluLaval Quadrivalent: 0.5 mL for all ages ≥6 months. 2

Rationale for Annual Vaccination

Why Annual Vaccination Is Necessary:

  • Antigenic drift causes circulating influenza strains to change annually, requiring updated vaccine formulations. 1
  • Waning immunity occurs over months following vaccination, with antibody levels declining during the year even when vaccine strains remain unchanged—this decline is especially pronounced in elderly persons. 1, 3
  • Annual vaccination is required even when vaccine composition is unchanged from the previous season due to immunity decline. 1

Common Pitfalls and Caveats

Vaccination After Influenza Infection

  • No required waiting period after influenza infection before administering vaccine; the only consideration is that the person has clinically recovered from acute illness. 2, 3
  • High-risk individuals should be prioritized for vaccination immediately upon recovery to minimize their window of vulnerability. 3

Vaccine Effectiveness Variability

  • Effectiveness varies by season, virus subtype, and antigenic match, with some seasons showing reduced effectiveness (e.g., 16% against A(H3N2) in 2021-22 was not statistically significant). 5
  • Despite variable effectiveness against mild illness, vaccination continues to prevent serious outcomes (hospitalization, ICU admission, death) and should be administered throughout the season. 5, 6, 7, 8
  • Recent interim estimates show moderate to good effectiveness: 32-60% against outpatient illness and 63-78% against hospitalization in children; 36-55% against outpatient illness and 41-55% against hospitalization in adults. 6

Administration Route

  • IIV4 is administered intramuscularly: deltoid muscle for adults and older children; anterolateral thigh for infants and younger children. 2
  • LAIV4 is administered intranasally. 2

References

1
Guideline

Influenza Vaccination Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

2
Guideline

Influenza Vaccine Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3
Guideline

Influenza Vaccination Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

Is the current influenza (flu) vaccine effective this year?
Can I administer the influenza (flu) season 2025 vaccine now and the influenza (flu) season 2026 vaccine once it becomes available?
Can a supervaccine be administered to a patient who received an influenza (flu) vaccination 2 months ago?
Does a 32-month-old child who received influenza (flu) vaccine in previous years need another flu vaccine this year?
Can a 14-year-old patient who received Hepatitis B Vaccine (Engerix-B/Recombinant Hepatitis B Vaccine) , Meningococcal Conjugate Vaccine (MenACWY, Menveo), Measles, Mumps, and Rubella (MMR) Vaccine, Tetanus, Diphtheria, and Pertussis (Tdap) Vaccine, and Varicella Vaccine last week, with no record of influenza vaccination in the past year but due for one next month, get the flu shot now?
In patients (adults or children) with suspected bacteremia, sepsis, endocarditis, or other systemic infection, which blood culture bottle should be drawn first: aerobic or anaerobic?
In an otherwise healthy adult with a solitary T2 (≤4 cm, limited to the muscularis propria) colon cancer, is neoadjuvant chemotherapy recommended?
How should I manage a patient who develops an allergic reaction to prednisone?
What are the most common causes of acute liver failure in adults?
In a 43‑year‑old man in cardiac arrest with 45 minutes of CPR, 6 mg epinephrine, fixed pupils, and an initial shockable ventricular fibrillation rhythm that converted but no palpable pulse, can audible heart sounds occur with pulseless electrical activity and do they indicate a true pulse?
In a hypermobile Ehlers‑Danlos syndrome patient with suspected postural tachycardia syndrome who develops tachycardia and palpitations while seated (normotensive) that resolve with recumbence and foot elevation, does this pattern suggest a specific differential diagnosis or is it typical of postural tachycardia syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question